Moderna coronavirus vaccine granted ‘fast-track’ designation from FDA

Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.

Moderna announced Tuesday its fast-track designation awarded by the Food and Drug Administration (FDA) to accelerate the development of an effective COVID-19 vaccine.

CLICK HERE FOR FULL CORONAVIRUS COVERAGE

The purpose of fast track is to expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need, Moderna officials wrote in a company statement.

FAUCI ‘CAUTIOUSLY OPTIMISTIC’ A CORONAVIRUS VACCINE CANDIDATE WILL BE EFFECTIVE

“Fast Track designation underscores the urgent need for a vaccine against the novel coronavirus,” Tal Zaks, M.D., Ph.D., chief medical officer at Moderna, wrote in a company statement. “As we await the full set of clinical data from the NIAID-led Phase 1 study, we are actively preparing for our Phase 2 and Phase 3 clinical studies to continue learning about the potential of mRNA-1273 to protect against SARS-CoV-2.”

The FDA gave its approval for Moderna to enter a Phase II study for mRNA-1273, which is expected to begin shortly.

Moderna said a Phase 3 study could begin in the early summer of this year.